Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. - Kumar, K; Wigfield, S; Gee, H; Devlin, C; Singleton, D; Li, J; Buffa, F; Huffman, M; Sinn, A; Silver, J; Turley, H; Leek, R; et al. (Journal of molecular medicine (Berlin, Germany), 2013)